Lilly adds food, travel to doc-payment report

Eli Lilly ($LLY) expanded its disclosure on payments to doctors and healthcare groups, adding food and other non-cash gifts to the mix. In its latest quarterly payments report, mandated by a corporate integrity agreement with the feds, the drugmaker toted up $48.1 million in compensation, research spending and other payments.

For more than a year, the company has been detailing payments to doctors who speak, consult and advise on Lilly's behalf. This time around, those payments totaled $13.6 million. The new registry also includes "transfers of value," e.g. business meals, travel expenses and so on, spokesman J. Scott MacGregor told Medical Marketing & Media. The company also disclosed some $30 million in payments to hospitals and universities for clinical trial costs.

As MM&M points out, all drugmakers will have to add those transfers-of-value disclosures to their reporting starting in 2013. Everything from speaking fees to entertainment to food will have to be recorded; only drug samples aren't covered by the mandate. Besides Lilly, Pfizer has begun reporting this type of payment, and several other drugmakers are disclosing payments to doctors.

- get the story from MM&M

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.